foxo4-dri peptide senolytic 2023 2024 study Development of a novel by precise disruption of FOXO4-p53 complex Senolytics: charting a new course

In some instances, upon administration of a controlled release auris formulation or composition described herein (e.g., a formulation comprising a therapeutic agent), drug concentrations relative to the binding constants of one or more otic receptors are relevant in determining a biologically meaningful PK profile or the minimum concentration of an active agent required for a therapeutic effect

By ensuring a clear path, you're not just protecting the peptide from degradation

I think thats low-hanging fruit that we could really get better at, in terms of rehab

[DOI] [PMC free article] [PubMed] [Google Scholar] Daz-Mireles E